People - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

People
People on the move

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 9

Corona, CA (Aug. 2)Watson Pharmaceuticals announced that Allen Chao, Ph.D., 61, its chairman, president and chief executive officer, will retire as president and chief executive officer, effective September 4, 2007. Chao will be succeeded by Paul M. Bisaro, 46, currently president and chief operating officer of Barr Pharmaceuticals (Woodcliff Lake, NJ), who has been named president and chief executive officer of Watson, effective September 4, 2007. Bruce L. Downey, Barr's chairman and chief executive officer, will assume these responsibilities on an interim basis.

Abbott Park, IL (Aug. 3)—Richard A. Gonzalez, president and chief operating officer, and a member of Abbott's board of directors, plans to retire after a 30-year career with the company. Gonzalez will remain with Abbott until Sept. 30, 2007.

Thousand Oaks, CA (Aug. 2)Amgen announced that Dennis Fenton, executive vice-president of operations, has elected to retire at the end of 2007 after 25 years with the company.

San Diego, CA (Aug. 2)— BioDuro, a life-sciences outsourcing company for the pharmaceutical and biotechnology industry with headquarters in San Diego, CA, and laboratory facilities in Beijing, China, appointed Steven M. Hutchins to the position of vice-president, business development and collaboration management.

Paris (Aug. 1)—David J. Williams relinquished his titles of president and chief executive officer of Sanofi Pasteur, the vaccines division of the Sanofi-Aventis Group . He will continue to serve as chairman of the board of Sanofi Pasteur until January 16, 2008, which will also mark his 30th anniversary with the company. His successor will be Wayne Pisano, formerly senior vice-president, global commercial operations and corporate strategy.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here